| Tamoxifen pharmacogenetics and metabolism: results from the prospective CYPTAM study A Sanchez-Spitman, V Dezentjé, J Swen, DJAR Moes, S Böhringer, ... Journal of Clinical Oncology 37 (8), 636-646, 2019 | 92 | 2019 |
| Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen AB Sanchez-Spitman, JJ Swen, VO Dezentje, D Moes, H Gelderblom, ... Expert Review of Clinical Pharmacology 12 (6), 523-536, 2019 | 81 | 2019 |
| Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism GHJ Sanchez Spitman AB, Moes DJAR, Gelderblom H, Dezentje VO, Swen JJ Eur J Clin Pharmacol. 73 (12), 1589–1598, 2017 | 52 | 2017 |
| Genetic polymorphisms of 3′-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy AB Sanchez-Spitman, VO Dezentjé, JJ Swen, D Moes, H Gelderblom, ... Breast cancer research and treatment 172, 401-411, 2018 | 26 | 2018 |
| The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen AB Sanchez-Spitman, DJAR Moes, H Gelderblom, VO Dezentjé, JJ Swen, ... Pharmacogenomics 18 (12), 1125-1132, 2017 | 26 | 2017 |
| Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse AB Sanchez-Spitman, JJ Swen, VO Dezentjé, D Moes, H Gelderblom, ... Scientific reports 11 (1), 415, 2021 | 15 | 2021 |
| Exposure–response analysis of endoxifen serum concentrations in early-breast cancer AB Sanchez-Spitman, DJAR Moes, JJ Swen, VO Dezentjé, D Lambrechts, ... Cancer Chemotherapy and Pharmacology 85, 1141-1152, 2020 | 11 | 2020 |
| A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen. AB Sanchez-Spitman, VO Dezentje, JJ Swen, DJAR Moes, E Batman, ... Journal of Clinical Oncology 36 (15_suppl), 523-523, 2018 | 7 | 2018 |
| Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer ETD Souwer, A Sanchez-Spitman, D Moes, H Gelderblom, JJ Swen, ... Breast cancer research and treatment 199 (3), 471-478, 2023 | 3 | 2023 |
| Incidence of clinically significant toxicities in patients with high endoxifen concentrations SL Groenland, AB Sanchez-Spitman, D Moes, SL Koolen, VO Dezentje, ... Annals of Oncology 29, viii82, 2018 | 3 | 2018 |
| A genome‐wide association study of endoxifen serum concentrations and adjuvant tamoxifen efficacy in early‐stage breast cancer patients AB Sanchez‐Spitman, S Böhringer, VO Dezentjé, H Gelderblom, JJ Swen, ... Clinical Pharmacology & Therapeutics, 2024 | 2 | 2024 |
| Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM Reply HJ Guchelaar, A Sanchez-Spitman, V Dezentjé, S Bohringer, J Swen, ... Journal of Clinical Oncology 37 (22), 1984-+, 2019 | 2 | 2019 |
| Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort AM Mc Laughlin, T Helland, F Klima, SLW Koolen, RHN van Schaik, ... Clinical Pharmacology & Therapeutics, 2024 | | 2024 |
| Personalizing tamoxifen therapy in adjuvant therapy: a brief summary of the ongoing discussion A Sanchez-Spitman, HJ Guchelaar Expert Review of Clinical Pharmacology 16 (2), 93-95, 2023 | | 2023 |
| Tamoxifen pharmacogenetics and pharmacokinetics in early breast cancer AB Sanchez Spitman update 32, 2255-2269, 2014 | | 2014 |
| Platform Presentations G Dranitsaris, S Edwards, J Edwards, R Abbott | | 2010 |
| PACIENTE CON HIPERTENSIÓN PULMONAR: EVALUACIÓN DE POSIBLES INTERACCIONES ABS Spitman, MA Collado | | |
Hans GelderblomLUMCVerified email at lumc.nl
Hans GelderblomLUMCVerified email at lumc.nl